LEONID Lung cancEr fusiOn geNes: a new dIagnostic Device

Leonid EU opportunities Italian success - A revolutionary diagnostic device for lung cancer

PROGRAM FINAL EVENT 

10:00 Welcome to Diatech!
Hall, 2° flor

11:00 Presentation of the results of the project LEONID
Auditorium, 2° flor

Welcome greetings

Fabio Biondi - Diatech Pharmacogenetics  President

Luca Ceriscioli - President of Regione Marche Mariangela Siler DG research and innovation in Health, Ministry of Health

11:30 Regional policies in the health field - Manuela Bora  Productive Activities of the Marche Region

11:50 Italian companies in European and national programs for R&I - Nicoletta Amodio Manager Research and Innovation, Confindustria

12:10 The history and the results of the project LEONID - Maura Menghi Scientific Director Diatech Pharmacogenetics

12:30 LEONID clinical study: presentation of preliminary results - Paola Ulivi Settore Biomarcatori e Medicina Personalizzata- Diagnostica molecolare III livello, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) IRCCS Meldola

12:45 Myriapod® Lung Fusion Genes in the clinical practice  - Gabriella Fontanini Dipartimento di Patologia Medica Molecolare e di Area Critica, University of Pisa

13:00 Networking lunch, 2° flor

Leonid Save the Date Final Event December 1st 2016

Download Leonid brochure

XVIII CONGRESSO NAZIONALE AIOM - ROMA, October 28th-30th 2016

Leonid’s product and impacts

• RealQuant® Lung Fusion Genes, medical device validated for in vitro diagnostic use under the 98/79/EC directive.
• One test for multiple biomarkers detection and quantification (ALK, ROS1 and RET gene rearrangements in the same reaction) --> reduction of costs.
• Identification of the main fusion genes in the same well.
• Standardized results without personal interpretation and simplification of the medical report thanks to a dedicated software for secondary analysis on Nanostring® output data --> reduction of data decoding errors.
• Easy-of-use (only 4 pipetting steps) --> reduction of hands-on-time and manual errors. 
• Higher throughput (up to 10 samples per run).
• Faster workflow (from FFPE tissue to data in less than 2 days).
• Quality control of pre-analytical and analytical steps.
• Performance validated in a multicenter clinical study at Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell'Area Critica, Università di Pisa - Azienda Ospedaliero Universitaria Pisana (Pisa) and at Laboratorio di Bioscienze, Diagnostica Molecolare di III livello - Biomarcatori e Medicina Personalizzata, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) IRCCS (Meldola). 

Horizon 2020 programma quadro in ricerca e innovazione: le varie opportunità per la salute, cenni alla progettazione e confronto tra le esperienze pubblico - private  

Rome 14th July Ministry of Health Auditorium, Viale Giorgio Ribotta 5, Rome

Maura Menghi Diatech Pharmacogenetics Scientific Directors and IRCSS Meldola Staff take part in session number 3:

Esperienze vincenti in Horizon 2020: il valore della collaborazione tra pubblico e privato

• Fabrizia Lattanzio, INRCA, Progetto Scop

• Marina Cuttini, Ospedale Pediatrico Bambino Gesù, SHIPS

• Marco Molinari, Fondazione Santa Lucia, Progetto NISCI

• Costantino Bongiorno, WeMake, Progetto Opencare

• Evert Jan Hoogerwerf, AIAS, Progetto ProACT (contributo video)

• Maura Menghi, Diatech Pharmacogenetics, Progetto LEONID

• Michele Nicoletta, ABBVIE

• Sigma-tau (tbc)